View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 3, 2017updated 13 Jul 2022 10:08am

SELLAS and Merck to begin Phase I/II cancer combination clinical trial

Biopharmaceutical firm SELLAS Life Sciences Group has entered a clinical trial collaboration and supply agreement with Merck to conduct a combination clinical trial targeting multiple cancer types.

Biopharmaceutical firm SELLAS Life Sciences Group has entered a clinical trial collaboration and supply agreement with Merck to conduct a combination clinical trial targeting multiple cancer types.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

As part of the deal, a Phase I/II combination clinical trial will be initiated to evaluate SELLAS’ Wilms tumour-1 (WT1) targeting peptide immunotherapeutic agent, galinpepimut-S, with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with five cancer indications, including both hematologic malignancies and solid tumours.

The trial is designed to determine if the administration of galinpepimut-S in combination with KEYTRUDA has the potential to show clinical activity in the presence of macroscopic disease, where monotherapy with either agent would have a more limited effect.

The company noted that the foundation for the trial is based upon the presumed immunobiologic and pharmacodynamic synergy between the two agents, where the negative influence of tumour microenvironment factors on the immune response is mitigated by PD-1 inhibition.

It then allows the patients’ own immune cells to invade and destroy cancerous growth deposits specifically sensitised against WT1.

SELLAS vice-chairman and chief executive officer Angelos Stergiou said: “SELLAS is enthused to embark upon this trial with MSD as we look to expand the utility of galinpepimut-S in combination with other agents.

“The KEYTRUDA/galinpepimut-S active immunotherapy combination is positioned to exploit the unique features of each of these two agents through potential synergistic immune-based mechanisms of antitumor action.”

“The KEYTRUDA/galinpepimut-S active immunotherapy combination is positioned to exploit the unique features of each of these two agents through potential synergistic immune-based mechanisms of antitumor action.

“If positive, this clinical effort will allow us to evaluate indications, whereby galinpepimut-S and KEYTRUDA could be further studied in combination, providing the basis for a potentially promising cancer immunotherapy approach in the future.”

Scheduled to begin in the first half of next year, the trial will use the combination to explore the cancer indications such as colorectal, ovarian, small cell lung, triple-negative breast and acute myeloid leukaemia (AML).

It will assess the efficacy and safety of the combination, comparing overall response rates (ORRs) and immune response markers achieved with the combination versus prespecified rates based on those seen with KEYTRUDA alone in comparable patient populations.

Currently, galinpepimut-S is expected to enter a pivotal, Phase III clinical trial in patients with AML and is also in various development phases in multiple myeloma (MM) and ovarian cancer.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena